These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24227660)

  • 1. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.
    Bays HE; Weinstein R; Law G; Canovatchel W
    Obesity (Silver Spring); 2014 Apr; 22(4):1042-9. PubMed ID: 24227660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
    Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
    Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Stenlöf K; Cefalu WT; Kim KA; Alba M; Usiskin K; Tong C; Canovatchel W; Meininger G
    Diabetes Obes Metab; 2013 Apr; 15(4):372-82. PubMed ID: 23279307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
    Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
    PLoS One; 2014; 9(8):e105638. PubMed ID: 25166023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Yue D; David-Neto E; Xi L; Figueroa K; Wajs E; Usiskin K; Meininger G
    Diabetes Obes Metab; 2013 May; 15(5):463-73. PubMed ID: 23464594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.
    Hollander P; Bays HE; Rosenstock J; Frustaci ME; Fung A; Vercruysse F; Erondu N
    Diabetes Care; 2017 May; 40(5):632-639. PubMed ID: 28289041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
    Leiter LA; Yoon KH; Arias P; Langslet G; Xie J; Balis DA; Millington D; Vercruysse F; Canovatchel W; Meininger G
    Diabetes Care; 2015 Mar; 38(3):355-64. PubMed ID: 25205142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
    Sinclair A; Bode B; Harris S; Vijapurkar U; Mayer C; Fung A; Shaw W; Usiskin K; Desai M; Meininger G
    BMC Endocr Disord; 2014 Apr; 14():37. PubMed ID: 24742013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
    Nyirjesy P; Sobel JD; Fung A; Mayer C; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2014 Jun; 30(6):1109-19. PubMed ID: 24517339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
    Rosenstock J; Aggarwal N; Polidori D; Zhao Y; Arbit D; Usiskin K; Capuano G; Canovatchel W;
    Diabetes Care; 2012 Jun; 35(6):1232-8. PubMed ID: 22492586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
    Weir MR; Januszewicz A; Gilbert RE; Vijapurkar U; Kline I; Fung A; Meininger G
    J Clin Hypertens (Greenwich); 2014 Dec; 16(12):875-82. PubMed ID: 25329038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
    Weir MR; Kline I; Xie J; Edwards R; Usiskin K
    Curr Med Res Opin; 2014 Sep; 30(9):1759-68. PubMed ID: 24786834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
    Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
    J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.